Meropenem 1GM+Tazobactum 125Mg

MEROTATE TZ 1.125 INJ  from Criticine Care contains 1 gm of Meropenem and 125 mg of tazobactam, a combination of antibiotics that is used to treat certain serious bacterial infections. Meropenem is a broad-spectrum antibiotic, while Tazobactam helps protect the antibiotic from certain bacterial enzymes that can reduce its effectiveness.

This medicine is given by injection and is generally used in hospital and critical care settings when intravenous antibiotic treatment is required. It may be used against a range of susceptible Gram-positive and Gram-negative bacterial infections. MEROTATE TZ 1.125 INJ should be used only under the direction of a qualified healthcare professional.

Clinical Applications of MEROTATE TZ 1.125 Injection

Depending on the diagnosis, susceptibility of the causative organism, and medical advice, Meropenem and Tazobactam Injection may be considered for certain serious bacterial infections, including complicated infections of the respiratory tract, urinary tract, abdomen, skin and soft tissues, and other infections requiring injectable antibacterial treatment. The exact indication and duration of therapy should be determined by the treating healthcare professional.

Meropenem and Tazobactam Injection PCD Pharma Franchise Opportunity with Criticine Care

Criticine Care offers a quality-assured Meropenem and Tazobactam injection under their brand name, MEROTATE TZ 1.125 INJ. This injection can be a useful addition to a Critical Care PCD Pharma Franchise product range for pharma professionals who are dealing in injectable medicines. A dedicated critical care portfolio can help franchise partners supply products to hospitals, clinics, nursing homes, and healthcare institutions where injectable medicines are commonly used.

The franchise opportunity can be suitable for pharma distributors, stockists, medical representatives, and other eligible professionals who want to establish or expand their pharmaceutical business with a focused Critical Care portfolio.

Why Choose MEROTATE TZ 1.125 Injection for Your Franchise Portfolio?

• Meropenem 1 g + Tazobactam 125 mg injectable formulation
• Broad-spectrum antibacterial combination
• Part of the Critical Care / Injectable product segment
• Suitable for hospital- and clinical-focused portfolios
• Opportunity to expand your range of injectable antibiotics
• Supports a specialised Critical Care PCD Pharma Franchise portfolio

Partner with Criticine Care

For pharma professionals looking to expand their Critical Care PCD Pharma Franchise portfolio, MEROTATE TZ 1.125 INJ provides an opportunity to add a Meropenem & Tazobactam injectable combination to their product range. With the growing requirement for specialised pharmaceutical products in hospital and clinical settings, critical care injectables can be an important addition to a focused pharma portfolio.

If you are looking for a Meropenem and Tazobactam Injection PCD Pharma Franchise, MEROTATE TZ 1.125 INJ by Criticine Care can be considered as part of a specialised Critical Care product portfolio. Contact Criticine Care to explore product details, franchise availability, territory opportunities, and business terms.